Connection

DAVID LONARD to Nuclear Proteins

This is a "connection" page, showing publications DAVID LONARD has written about Nuclear Proteins.
Connection Strength

0.423
  1. The REG? inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells. Nat Commun. 2020 08 06; 11(1):3904.
    View in: PubMed
    Score: 0.106
  2. Uterine function in the mouse requires speckle-type poz protein. Biol Reprod. 2018 06 01; 98(6):856-869.
    View in: PubMed
    Score: 0.091
  3. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation. Int J Biol Sci. 2015; 11(5):618-28.
    View in: PubMed
    Score: 0.073
  4. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6997-7002.
    View in: PubMed
    Score: 0.064
  5. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene. 2011 Oct 20; 30(42):4350-64.
    View in: PubMed
    Score: 0.056
  6. Proteomic analysis of coregulators bound to ERa on DNA and nucleosomes reveals coregulator dynamics. Mol Cell. 2013 Jul 25; 51(2):185-99.
    View in: PubMed
    Score: 0.016
  7. Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II. J Steroid Biochem Mol Biol. 2005 Mar; 94(4):337-46.
    View in: PubMed
    Score: 0.009
  8. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. Mol Endocrinol. 2003 Jul; 17(7):1315-31.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.